ScholarLens Back to search
2012•Multiple Sclerosis JournalRequires access

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Alice Laroni, Davide Brogi, V. Milesi, L Abate, Antonio Uccelli, Gianluigi Mancardi

Open publisher page 31 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 31 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Fingolimod, Natalizumab, Multiple sclerosis, Medicine, Disease, Clinical neurology, Internal medicine, Neuroscience

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption — Research Paper | ScholarLens